В обзоре дана характеристика современного состояния исследований в области изучения лекарственной чувствительности M. tuberculosis: методы, результаты изучения чувствительности/устойчивости к основным препаратам, используемым для лечения туберкулеза, значение оценки уровня устойчивости/чувствительности штаммов M. tuberculosis,
выделенных от больных, для определения оптимальных схем химиотерапии.
Ключевые слова: M. tuberculosis, лекарственная чувствительность/устойчивость
Литвинов Виталий Ильич – научный руководитель ГБУЗ «Московский городской научно-практический центр борьбы
с туберкулезом Департамента здравоохранения города Москвы», доктор медицинских наук, профессор, академик РАН
Адрес: 107014, г. Москва, ул. Стромынка, д. 10
Тел. + 7 (495) 268-04-15
e-mail: mnpcbtlv@yandex.ru
Макарова Марина Витальевна – ведущий научный сотрудник отдела проблем лабораторной диагностики туберкулеза
и патоморфологии ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы», доктор биологических наук
Адрес: 107014, г. Москва, ул. Стромынка, д. 10
Тел. +7 (916) 688-98-25
Факс +7 (495) 964-86-37
e-mail: makarova75@yandex.ru
Носова Елена Юрьевна – ведущий научный сотрудник отдела проблем лабораторной диагностики туберкулеза и патоморфологии ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы», доктор биологических наук
Адрес: 107014, г. Москва, ул. Стромынка, д. 10
Тел. +7 (495) 603-30-33
Факс +7 (499) 785-20-82
e-mail: rna68@rambler.ru
Сафонова Светлана Григорьевна – заведующая отделом проблем лабораторной диагностики туберкулеза и патоморфологии ГБУЗ города Москвы «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы», доктор биологических наук
Адрес: 107014, г. Москва, ул. Стромынка, д. 10
Тел. +7 (495) 603-30-33
Факс +7 (499) 785-20-82
e-mail: safonova.s.g.@inbox.ru
1. Лабораторные исследования при туберкулезе / под ред. Литвинова В.И., Мороза А.М. – М.: МНПЦБТ, 2013. – 342 с.
2. О совершенствовании противотуберкулезных мероприятий в Российской Федерации / Приказ Министерства здравоохранения Российской Федерации № 109 от 21.03.2003 г. [Электронный ресурс] URL: http://www.consultant.ru/document/cons_doc_LAW_100829/ (Дата обращения
12.07.2016).
3. Abuali М., Katariwala R., LaBombardi V. A comparison of the Sensitive® MYCOTB panel and the agar proportion method for the susceptibility testing of
Mycobacterium tuberculosis // Eur. J. Clin. Microbiol. Infect. Dis. – 2011. – Vol. 31. – N. 5. – P. 835-839.
4. Banu S., Rahman S., Khan M. et аl. Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates
in a single laboratory // J Clin. Microbiol. – 2014. – Vol. 52. – N. 1. – P. 156-163.
5. Böttger E. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing // Clin. Microbiol. Infect. – 2011. – Vol. 17. – N. 8. – P. 1128-1134.
6. Brown-Elliott B., Wallace R., Crist C. et аl. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing
mycobacteria // Antimicrob. Agents Chemother. – 2002. – Vol. 46. – N. 10. – Р. 3283-3285.
7. Brown-Elliott B., Nash K., Wallace R. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous
mycobacteria // Clin. Microbiol. Rev. – 2012. – Vol. 25. – N. 3. – P. 545-582.
8. Cavalieri S., Biehle J., Sanders W. Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium
tuberculosis // Phys. Rev. A. – 1995. – Vol. 51. – N. 4. – P. 2974-2981.
9. Cambau E., Viveiros M., Machado D. et al. Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in European
multicenter study // J. Antimicrob. Chemother. – 2015. – Vol. 70. – P. 686-696.
10. Cavusoglu C., Soyler I., Akinci P. Activities of linezolid against nontuberculous mycobacteria // New. Microbiol. – 2007. – Vol. 30. – N. 4. – P. 411-414.
11. Chiang C., Centis R., Migliori G. Drug-resistant tuberculosis: past, present, future // Respirology. – 2010. – Vol. 15. – N. 3. – P. 413-32.
12. Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of Mycobacteria, Nocardiae and other aerobic Actinomycetes // Approved standard
second edition. – 2011. – Vol. 31. – N. 5. – P. 1-61.
13. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. – Geneva: WHO, 2014.
14. Daley C., Caminero J. Management of multidrug resistant tuberculosis // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – P. 44-59.
15. Davies Forsman L., Schön T., Simonsson U. et al. Intra- and extracellular activities of trimethoprim-sulfamethoxazole against susceptible and multidrugresistant Mycobacterium tuberculosis // Antimicrob. Agents Chemother. – 2014. – Vol. 58. – N. 12. – P. 7557-7559.
16. Dheda K., Gumbo T., Gandhi N. et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis // Lancet. Respir. Med. –
2014. – Vol. 2. – N. 4. – P. 321-338.
17. Fitzwater S., Sechler G., Jave O. et al. Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay // Eur. Respir J. – 2013. –
Vol. 41. – N. 5. – P. 1163-1171.
18. Gonzalo X., Casali N., Broda A. et al. Combination of amikacin and doxycycline against multidrug-resistant and extensively drug-resistant tuberculosis //
Int. J. Antimicrob. Agents. – 2015. – Vol. 45. – N. 4. – P. 406-412.
19. Gorzynski E., Gutman S., Allen W. Author information comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference
fluoroquinolones, and a new macrolide, clarithromycin // Antimicrob. Agents Chemother. – 1989. – Vol. 33. – N. 4. – P. 591-592.
20. Guidelines for the programmatic management of drug-resistant tuberculosis. – Geneva: WHO, 2011.
21. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and
population pharmacokinetic variability // Antimicrob. Agents Chemother. – 2010. – Vol. 54. – N. 4. – P. 1484-1491.
22. Gunther G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges // Clin. Med. – 2014. –
Vol. 14. – N. 3. – P. 279-85.
23. Hall L., Jude K., Clark S. et al. Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex for first and second line drugs by broth dilution i
n a microtitre plate format // J. Vis. Exp. – 2011. – Vol. 24. – N. 52. – P. 3094.
24. Hall L., Jude K., Clark S. et al. Evaluation of the Sensititre MycoTB plate for susceptibility testing of the Mycobacterium tuberculosis complex against first- and
second-line agents// J. Clin. Microbiol. – 2012.– Vol. 50. – N. 11.– P. 3732-3734.
25. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteriology // Am. Rev. Respir. Dis. – 1988. – Vol. 137. – N. 5. – P. 1217-1222.
26. Heifets L. Drug susceptibility in the chemotherapy of mycobacterial infections. – CRC press, 1991. – 212 p.
27. Heifets L. Clinical mycobacteriology. Drug susceptibility testing // Clin. Lab. Med. – 1996. – Vol. 16. – N. 3. – P. 641-656.
28. Huang T., Lee S., Tu H. et al. Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin
and ethionamide // J. Antimicrob. Chemother. – 2004. – Vol. 53. – N. 4. – P. 600-603.
29. Huang T., Kunin C., Yan B. et al. Susceptibility of Mycobacterium tuberculosis to sulfamethoxazole, trimethoprim and their combination over a 12 year
period in Taiwan // J. Antimicrob. Chemother. – 2012. – Vol. 67. – N. 3. – P. 633-667.
30. van Ingen J., Boeree M., van Soolingen D. et al. Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria
interrelated? // Infect. Genet. Evol. – 2012. – Vol. 12. – N. 4. – P. 832-837.
31. van Ingen J., Boeree M., van Soolingen D., Mouton J. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria // Drug. Resist.
Updat.– 2012.– Vol. 15. – N. 3. – P. 149-161.
32. van Ingen J., Simons S., de Zwaan R. et al. Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium
tuberculosis complex isolates // J. Clin. Microbiol. – 2010. – Vol. 48. – N. 8. – P. 2749-2753.
33. Janin Y. Antituberculosis drugs: ten years of research. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9
broth // Bioorg. Med. Chem. – 2007. – Vol. 15. – N. 7. – P. 2479-2513.
34. Kalokhe A., Shafiq M., Lee J. et al. Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing // Am. J. Med. Sci. – 2013. –
Vol. 345. – N. 2. – P. 143-148.
35. Kurbatova E., Cavanaugh J., Shah N. et al. Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs //
Int. J. Tuberc. Lung. Dis. – 2012. – Vol. 16. – N. 3. – P. 355-357.
36. Kurbatova E., Dalton T., Ershova J. et al. Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries // Emerg. Infect. Dis. –
2015. – Vol. 21. – N. 6. – P. 977-983.
37. Lee J., Armstrong D., Ssengooba W. et al. Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second — line
drugs //Antimicrob. Agents Chemother. – 2014. – Vol. 58. – N. 1. – P. 11-18.
38. Lin S., Desmond E., Bonato D. et al. Multicenter evaluation of BACTEC MGIT 960 system for second-line drug susceptibility testing of Mycobacterium
tuberculosis complex // J. Clin. Microbiol. – 2009. – Vol. 47. – N. 11. – P. 3630-3634.
39. Luna-Herrera J., Martínez-Cabrera G., Parra-Maldonado R. et al. Use of receiver operating characteristic curves to assess the performance of a microdilution
assay for determination of drug susceptibility of clinical isolates of Mycobacterium tuberculosis // Eur. J. Clin. Microbiol. Infect. Dis. – 2003. – Vol. 22. – N. 1. –
P. 21-27.
40. Lynch J. Multidrug-resistant Tuberculosis // Med. Clin. North. Am. – 2013. – Vol. 97. – N. 4. – P. 553-579
41. Matteelli A., Roggi A., Carvalho A. Extensively drug-resistant tubercu-losis: epidemiology and management// Clin. Epidemiol. – 2014. – Vol. L. – N. 6. –
P. 111–118.
42. Mitchison D., Davies G. Assessment of the efficacy of new anti-tuberculosis drugs // Open. Infect. Dis. J. – 2008. – Vol. 2. – P. 59-76.
43. Mpagama S., Houpt E., Stroup S. et al. Application of quantitative second-line drug susceptibility at a multidrug-resistant tuberculosis hospital
in Tanzania // BMC Infect. Dis. – 2013. – Vol. 13. – P. 432-441.
44. Pfyffer G., Bonato D., Ebrahimzadeh A. et al. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical
second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media // J. Clin. Microbiol. –
1999. – Vol. 37. – N. 10. – P. 3179-3186.
45. Pholwat S., Heysell S., Stroup S. et al. Rapid first- and second-line drug susceptibility assay for Mycobacterium tuberculosis isolates by use of quantitative PCR //
J. Clin. Microbiol. – 2011. – Vol. 49. – N. 1. – P. 69-75.
46. Rivers E., Mancera R. New anti-tuberculosis drugs with novel mechanisms of action // Curr. Med. Chem. – 2008. – Vol. 15. – N. 19. – P. 1956-1967.
47. Rodrigues C., Jani J., Shenai S. et al. Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the BACTEC MGIT 960
System // Int. J. Tuberc. Lung. Dis. – 2008. – Vol. 12. – N. 12. – P. 1449-1455.
48. Ruiz-Serrano M., Alcalá L., Martínez L. et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible
or resistant to first-line antituberculosis drugs // Antimicrob. Agents Chemother. – 2000. – Vol. 44. – N. 9. – P. 2567-2568.
49. Rüsch-Gerdes S., Pfyffer G., Casal M. et al. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium
tuberculosis to classical second-line drugs and newer antimicrobials // J. Clin. Microbiol. – 2006. – Vol. 44. – N. 3. – P. 688-692.
50. Sharma M., Thibert L., Chedore P. et al. Canadian multicenter laboratory study for standardized second-line antimicrobial susceptibility testing of
Mycobacterium tuberculosis // J. Clin. Microbiol. – 2011. – Vol. 49. – N. 12. – P. 4112-4116.
51. Smith Т., Wolff K., Nguyen L. Molecular biology of drug resistance in Mycobacterium tuberculosis // Curr. Top. Microbiol. Immunol. – 2013. – Vol. 374. –
P. 53-80.
52. Somasundaram S., Paramasivan N. Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods //
Chemotherapy. – 2006. – Vol. 52. – N. 4. – P. 190-195.
53. Tomioka H., Sato K., Saito H. Antimycobacterial activities of a new quinolone, sparfloxacin // Kekkaku. – 1991. – Vol. 66. – N. 10. – P. 643-649.
54. Use of liquid ТВ culture and drug susceptibility testing (DST) in low and medium income settings. summary report of the expert group meeting on the use
of liquid culture media. – Geneva: WHO, 2007
55. Wallace R., Nash D., Steele L., Steingrube V. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth //
J. Clin. Microbiol. – 1986. – Vol. 24. – N. 6. – P. 976-981.
56. Wallace R., Brown-Elliott B., Crist C. et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline,
minocycline, and doxycycline against isolates of nontuberculous mycobacteria // Antimicrob. Agents. Chemother. – 2002. – Vol. 46. – N. 10. – P. 3164-3167.
57. Wilson M. Recent advances in the laboratory detection of Mycobacterium tuberculosis complex and drug resistance // Clin. Infect. Dis. – 2011. – Vol. 52. –
N. 11. – P. 1350-1355.
58. Woods G., Williams-Bouyer N., Wallace R. et al. Multisite reproducibility of results obtained by two broth dilution methods for susceptibility testing of
Mycobacterium avium complex //J. Clin. Microbiol. – 2003. – Vol. 41. – N. 2. – P. 627-631.
59. Zignol M. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data // Drug Resist. Updat. – 2013. – Vol. 16. – N. 6. –
P. 108-115.
